We Are Positive on Momentum in U.S. Business, Says Novo Nordisk CEO

Dec.10 — Lars Fruergaard Jorgensen, chief executive officer at Novo Nordisk A/S, discusses the competitive environment for diabetes drugs, growth in the U.S. and innovation in the hemophilia space. He speaks on “Bloomberg Markets: European Open.”